https://www.taxtmi.com/news?id=61335 Two randomized trials showed SELUTION SLR Drug-Eluting Balloon (DEB) strategies were non-inferior to DES-based standard care: the SELUTION DeNovo trial (3,323 patients, 62 sites) reported 12 month target vessel failure of 5.3% with DEB versus 4.4% with DES for de novo lesions; the SELUTION4ISR trial reported 12 month target lesion failure of 15.2% with DEB versus 13.5% with standard-of-care (80% DES) for in stent restenosis. The SELUTION SLR uses Sustained Limus Release technology ( 90 days) and is commercially available in 65+ countries while investigational in the U.S. en-us Wed, 12 Nov 2025 10:46:03 +0530 Wed, 12 Nov 2025 10:46:03 +0530 TaxTMI RSS Generator https://www.taxtmi.com/news?id=61335 Two randomized trials showed SELUTION SLR Drug-Eluting Balloon (DEB) strategies were non-inferior to DES-based standard care: the SELUTION DeNovo trial (3,323 patients, 62 sites) reported 12 month target vessel failure of 5.3% with DEB versus 4.4% with DES for de novo lesions; the SELUTION4ISR trial reported 12 month target lesion failure of 15.2% with DEB versus 13.5% with standard-of-care (80% DES) for in stent restenosis. The SELUTION SLR uses Sustained Limus Release technology ( 90 days) and is commercially available in 65+ countries while investigational in the U.S. News - Wed, 12 Nov 2025 10:46:03 +0530 https://www.taxtmi.com/news?id=61335